We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Stock Moves -0.29%: What You Should Know
Read MoreHide Full Article
AbbVie (ABBV - Free Report) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same time, the Dow lost 0.62%, and the tech-heavy Nasdaq lost 1.71%.
Coming into today, shares of the drugmaker had gained 11.2% in the past month. In that same time, the Medical sector gained 0.53%, while the S&P 500 lost 7.03%.
The upcoming earnings release of AbbVie will be of great interest to investors. It is anticipated that the company will report an EPS of $2.51, marking an 8.66% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.92 billion, up 4.94% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $12.30 per share and a revenue of $59.52 billion, indicating changes of +21.54% and +5.66%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for AbbVie. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.15% lower. AbbVie is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, AbbVie is at present trading with a Forward P/E ratio of 17.43. This indicates a premium in contrast to its industry's Forward P/E of 14.74.
Investors should also note that ABBV has a PEG ratio of 1.46 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.32.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 66, placing it within the top 27% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Stock Moves -0.29%: What You Should Know
AbbVie (ABBV - Free Report) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same time, the Dow lost 0.62%, and the tech-heavy Nasdaq lost 1.71%.
Coming into today, shares of the drugmaker had gained 11.2% in the past month. In that same time, the Medical sector gained 0.53%, while the S&P 500 lost 7.03%.
The upcoming earnings release of AbbVie will be of great interest to investors. It is anticipated that the company will report an EPS of $2.51, marking an 8.66% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $12.92 billion, up 4.94% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $12.30 per share and a revenue of $59.52 billion, indicating changes of +21.54% and +5.66%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for AbbVie. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.15% lower. AbbVie is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, AbbVie is at present trading with a Forward P/E ratio of 17.43. This indicates a premium in contrast to its industry's Forward P/E of 14.74.
Investors should also note that ABBV has a PEG ratio of 1.46 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 1.32.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 66, placing it within the top 27% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.